BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7080-7085

  Branford, Susan ^a   Seymour, John F ^b   Grigg, Andrew ^b   Arthur, Chris ^c   Rudzki, Zbigniew ^a   Lynch, Kevin ^d   Hughes, Timothy ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Teva Pharmaceuticals Australia Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; MESSENGER RNA;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOLECULAR STABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MUTATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 37249016890     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0844     Document Type: Article

References (28)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Kantarjian HM, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
4. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-50.
5. Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004;104:1979-88.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2404-17.
7. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
8. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia 2003;17:2392-400.
9. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon α plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17:2401-9.
10. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-20.
11. Goldman JM, Hughes T, Radich J, et al. Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS study [abstract]. Blood 2005;106:51a.
12. Morley A. Quantifying leukemia. N Engl J Med 1998;339:627-9.
13. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
14. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
15. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-9.
16. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32.
17. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107:587-99.
18. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. In: Illand H, Hertzgerg M, Marlton P, editors. Myeloid leukemia: methods and protocols. Methods in molecular medicine. Vol. 125. Totawa (NJ): Humana Press; 2006. p. 69-92.
19. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
20. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. In: Illand H, Hertzgerg M, Marlton P, editors. Myeloid leukemia: methods and protocols. Methods in molecular medicine. Vol. 125. Totawa (NJ): Humana Press; 2006. p. 93-106.
21. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70.
22. Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon α. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-94.
23. Colombat M, Fort MP, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006;91:162-8.
24. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.
25. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006;12:1181-4.
26. Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006;24:2603-10.
27. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
28. Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology (Am Soc Hematol Educ Program) 2006:211-8.